Charles Schwab Investment Management Inc. Cuts Stake in RAPT Therapeutics, Inc. (NASDAQ:RAPT)

Charles Schwab Investment Management Inc. lessened its position in RAPT Therapeutics, Inc. (NASDAQ:RAPT) by 65.9% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 70,946 shares of the company’s stock after selling 137,192 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.20% of RAPT Therapeutics worth $143,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in RAPT. Los Angeles Capital Management LLC raised its holdings in RAPT Therapeutics by 138.1% during the third quarter. Los Angeles Capital Management LLC now owns 201,439 shares of the company’s stock worth $405,000 after purchasing an additional 116,853 shares in the last quarter. Exchange Traded Concepts LLC lifted its holdings in shares of RAPT Therapeutics by 244.7% in the 3rd quarter. Exchange Traded Concepts LLC now owns 89,076 shares of the company’s stock valued at $179,000 after buying an additional 63,235 shares during the period. Point72 Asset Management L.P. lifted its holdings in shares of RAPT Therapeutics by 176,725.0% in the 2nd quarter. Point72 Asset Management L.P. now owns 707,300 shares of the company’s stock valued at $2,157,000 after buying an additional 706,900 shares during the period. AQR Capital Management LLC purchased a new stake in shares of RAPT Therapeutics in the second quarter valued at approximately $270,000. Finally, Squarepoint Ops LLC acquired a new position in RAPT Therapeutics during the second quarter worth $329,000. Hedge funds and other institutional investors own 99.09% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on RAPT. Piper Sandler downgraded RAPT Therapeutics from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $8.00 to $2.00 in a report on Monday, November 11th. Wells Fargo & Company reduced their price objective on shares of RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating for the company in a research note on Tuesday, November 12th. HC Wainwright restated a “neutral” rating on shares of RAPT Therapeutics in a research report on Monday, November 25th. UBS Group dropped their target price on shares of RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating for the company in a report on Monday, September 9th. Finally, JPMorgan Chase & Co. lowered RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Monday, November 11th. One analyst has rated the stock with a sell rating, ten have given a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $9.50.

RAPT Therapeutics Stock Performance

RAPT stock opened at $0.81 on Friday. The stock’s 50 day moving average price is $1.53 and its 200 day moving average price is $2.27. The firm has a market cap of $28.24 million, a P/E ratio of -0.29 and a beta of 0.07. RAPT Therapeutics, Inc. has a 1 year low of $0.79 and a 1 year high of $27.35.

RAPT Therapeutics (NASDAQ:RAPT) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.09. On average, research analysts predict that RAPT Therapeutics, Inc. will post -2.86 earnings per share for the current year.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.